Terns’ oral weight-loss drug has shown promising results in early-stage studies

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9 per cent in an early-stage study, joining drugmakers vying for a share of the lucrative weight-loss market, and its shares rose 27 per cent on Monday. 

Teile diesen Beitrag:

BELIEBTE BEITRÄGE
FOLGEN SIE UNS
Like uns auf Facebook
Folge uns auf Twitter
Abonniere unseren Kanal
Tick Tack
LIVEÜBERTRAGUNG